Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Shares in SK Corp. took a six percent hike Wednesday after announcing plans to list its subsidiary SK Biopharmaceuticals to raise 959.3 billion won.
It will be South Korea's biggest stock market debut since May 2017, when mobile gaming firm Netmarble raised 2.7 trillion won.
SK Biopharmaceuticals' anti-epilepsy drug, Cenobamate, began to sell in the US this month after the US Food and Drug Administration approved it in November.
The company will sell about 25 percent of its shares, with the final pricing of the share offering expected to on June 18.
Mirae Asset Daewoo Securities analyst Chung Dae-ro projects the company's market value to reach five trillion won.
After the Covid-19 pandemic pushed South Korean companies to postpone listing plans, many smaller companies in the country are now preparing to go public as the health situation improves.
An investment banker noted that the mood has changed since April as the stock market recovers.
South Korea's benchmark Kospi stock index has increased by more than a third since March.
Other companies expected to go public this year include Big Hit, the music label behind South Korean boy band BTS, which is eyeing to raise nearly around 1.226 trillion won.
There's also Hyundai Card, the credit card unit of Hyundai Motor Group, which is preparing a 2.45 trillion won listing.
